NeRRe: Advancing Neurokinin Receptor Antagonists
Starting the year with a cash injection of £23m, 2012 GSK spin-out NeRRe Therapeutics intends to advance its neurokinin receptor antagonist pipeline towards late-stage clinical development. CEO Mary Kerr spoke to Scrip's Mike Ward at the 2017 Biotech Showcase in San Francisco.
You may also be interested in...
Finance Watch: Venture Capital On Track For Another Record Year
Private Company Edition: With $8.9bn raised in the second quarter, venture capital investment in biopharma companies reached its second highest quarterly total to date – behind only Q1 of this year. Also, Nimbus Therapeutics raised $105m and European drug developers get in on the VC action.
Funding Boom Time Continues For UK Life Sciences
Nearly £1.6bn was invested in the pharma, biotech and life sciences sector in the UK from March to May, which means £2.39bn has been raised in the year to date, more than in the whole of 2020.
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.